Further studies in syngeneic MDS/AML models are required to solidify the efficacy and safety of anti-CCRL2 ADC, but this agent appears to be a promising candidate for combination therapies for high-risk MDS/AML including TP53-mutated disease especially given the lack of effective antibody-based therapies in these disease subsets. Here, CCRL2 is linked to myelodysplastic syndrome.